NUVB
Nuvation Bio Inc.
NYSE · Healthcare · Biotechnology · US
$6.81
+0.59%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−15.6x
Market Cap
$2.39B
MomentumView details →
1D Return
+0.59%
YTD Return
−24.50%
RSI (14)
53.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−15.6x
Market Cap
$2.39B
RSI (14)
53.0
MomentumView details →
1D Return
+0.59%
YTD Return
−24.50%
SummaryUpdated Jun 1, 2026
Nuvation Bio Inc. (NASDAQ:NUVB) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in New York, New York. Originally incorporated as RePharmation Inc., the company changed its name to Nuvation Bio Inc. in April 2019 and went public in August 2020. The company focuses on developing innovative therapeutic candidates for oncology, with its lead asset taletrectinib approaching FDA approval with a PDUFA date of June 23, 2025.
Similar companies
Latest newsMore news →
Nuvation Bio reported second quarter 2026 financial results, with total revenue of $31.7 million including $23.2 million in net product revenue for IBTROZI, and cash and marketable securities of $661.0 million as of June 30, 2026.29d agoNuvation Bio Inc. issued $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032, with an option for underwriters to purchase an additional $37.5 million, generating approximately $241.2 million in net proceeds (approximately $277.6 million if the overallotment option is fully exercised).67d ago